An original Nurix announcement on 2026-09-29 reports a research milestone in the Pfizer DAC collaboration. Pfizer handles antibody conjugation and subsequent development. Global vepdegestrant development, manufacturing, and commercialization rights transferred to Rigel in June 2026.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
An original Nurix announcement on 2026-09-29 reports a research milestone in the Pfizer DAC collaboration. Pfizer handles antibody conjugation and subsequent development. Global vepdegestrant development, manufacturing, and commercialization rights transferred to Rigel in June 2026.
Program / service
Target / indication
Representative stage
Evidence & scope
Nurix–Pfizer DAC platform collaboration
DAC targets not disclosed; historical ER PROTAC co-development · Determined by the collaboration program
Platform / services
This record does not claim platform-wide human validation
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Pfizer and BioNTech announced FDA approval of the 2026–2027 XFG-adapted COMIRNATY formula for adults 65 and older and people ages 5–64 with at least one condition increasing the risk of severe COVID-19. The decision drew on existing clinical, nonclinical, and real-world platform evidence plus formulation-specific quality and nonclinical data. The label does not provide unrestricted use across all age groups.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
Proceedings of the National Academy of Sciences / PubMed
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
No named clinical candidate, antigen, intracellular target, or trial is disclosed for the DAC collaboration. The E1 grade of rights-transferred vepdegestrant does not automatically apply to DACs.
